Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Name: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
Published: 2017
License: Public Domain

City of Hope Medical Center · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

celllymphoma

grade 3b follicular lymphoma, recurrent b-cell lymphoma, unclassifiable, with features intermediate between dlbcl and classic hl, recurrent classic hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent primary mediastinal (thymic) large b-cell cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory b-cell lymphoma, unclassifiable, with features intermediate between dlbcl and classic hl, refractory classic hodgkin lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 836952
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.